1
|
Wang H, Ashton R, Hensel JA, Lee JH, Khattar V, Wang Y, Deshane JS, Ponnazhagan S. RANKL-Targeted Combination Therapy with Osteoprotegerin Variant Devoid of TRAIL Binding Exerts Biphasic Effects on Skeletal Remodeling and Antitumor Immunity. Mol Cancer Ther 2020; 19:2585-2597. [PMID: 33199500 DOI: 10.1158/1535-7163.mct-20-0378] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2020] [Revised: 07/24/2020] [Accepted: 10/06/2020] [Indexed: 02/01/2023]
Abstract
Complexities in treating breast cancer with bone metastasis are enhanced by a vicious protumorigenic pathology, involving a shift in skeletal homeostasis toward aggressive osteoclast activity and polarization of immune cells supporting tumor growth and immunosuppression. Recent studies signify the role of receptor activator of NF-κB ligand (RANKL) beyond skeletal pathology in breast cancer, including tumor growth and immunosuppression. By using an osteoprotegerin (OPG) variant, which we developed recently through protein engineering to uncouple TNF-related apoptosis-inducing ligand (TRAIL) binding, this study established the potential of a cell-based OPGY49R therapy for both bone damage and immunosuppression in an immunocompetent mouse model of orthotopic and metastatic breast cancers. In combination with agonistic death receptor (DR5) activation, the OPGY49R therapy significantly increased both bone remolding and long-term antitumor immunity, protecting mice from breast cancer relapse and osteolytic pathology. With limitations, cost, and toxicity issues associated with the use of denosumab, bisphosphonates, and chemotherapy for bone metastatic disease, use of OPGY49R combination could offer a viable alternate therapeutic approach.
Collapse
Affiliation(s)
- Hong Wang
- Department of Pathology, The University of Alabama at Birmingham, Birmingham, Alabama
| | - Reading Ashton
- Department of Pathology, The University of Alabama at Birmingham, Birmingham, Alabama
| | - Jonathan A Hensel
- Department of Pathology, The University of Alabama at Birmingham, Birmingham, Alabama
| | - Joo Hyoung Lee
- Department of Pathology, The University of Alabama at Birmingham, Birmingham, Alabama
| | - Vinayak Khattar
- Department of Pathology, The University of Alabama at Birmingham, Birmingham, Alabama
| | - Yong Wang
- Department of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama
| | - Jessy S Deshane
- Department of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama
| | | |
Collapse
|
2
|
Chypre M, Madel MB, Chaloin O, Blin-Wakkach C, Morice C, Mueller CG. Porphyrin Derivatives Inhibit the Interaction between Receptor Activator of NF-κB and Its Ligand. ChemMedChem 2017; 12:1697-1702. [PMID: 28885764 DOI: 10.1002/cmdc.201700462] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2017] [Revised: 08/28/2017] [Indexed: 11/10/2022]
Abstract
Receptor activator of NF-κB (RANK), a member of the TNF-receptor superfamily, plays an important role in bone resorption and stimulates immune and epithelial cell activation. Denosumab, a human monoclonal antibody that blocks the RANK ligand (RANKL), is approved for the treatment of osteoporosis and bone metastasis. However, a small molecule that inhibits the RANK-RANKL interaction would be beneficial to decrease cost and to facilitate treatments with orally available therapeutic agents. Herein we report the discovery of the first nonpeptidic inhibitors of RANK-RANKL interactions. In screening a chemical library by competitive ELISA, the porphyrin verteporfin was identified as a hit. Derivatives were screened, and the chlorin-macrocycle-containing pheophorbide A and purpurin 18 were found to bind recombinant RANKL, to inhibit RANK-RANKL interactions in the ELISA, and to suppress the RANKL-dependent activation of model cells and the differentiation of RANK-expressing precursors into osteoclasts. This discovery of a family of small molecules that inhibit RANK activation presents an initial basis for further development of nonpeptidic therapeutic agents targeting the interaction between RANK and RANKL.
Collapse
Affiliation(s)
- Mélanie Chypre
- Prestwick Chemical, PC SAS, 67400, Illkirch-Graffenstaden, France.,Université de Strasbourg, CNRS UPR 3572, Immunopathology and Therapeutic Chemistry, 67000, Strasbourg, France
| | - Maria-Bernadette Madel
- CNRS, LP2M, UMR7370, Faculté de Médecine, Nice, France.,Université Nice Sophia Antipolis, Nice, France
| | - Olivier Chaloin
- Université de Strasbourg, CNRS UPR 3572, Immunopathology and Therapeutic Chemistry, 67000, Strasbourg, France
| | - Claudine Blin-Wakkach
- CNRS, LP2M, UMR7370, Faculté de Médecine, Nice, France.,Université Nice Sophia Antipolis, Nice, France
| | | | - Christopher G Mueller
- Université de Strasbourg, CNRS UPR 3572, Immunopathology and Therapeutic Chemistry, 67000, Strasbourg, France
| |
Collapse
|
3
|
Cordeiro OG, Chypre M, Brouard N, Rauber S, Alloush F, Romera-Hernandez M, Bénézech C, Li Z, Eckly A, Coles MC, Rot A, Yagita H, Léon C, Ludewig B, Cupedo T, Lanza F, Mueller CG. Integrin-Alpha IIb Identifies Murine Lymph Node Lymphatic Endothelial Cells Responsive to RANKL. PLoS One 2016; 11:e0151848. [PMID: 27010197 PMCID: PMC4806919 DOI: 10.1371/journal.pone.0151848] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2015] [Accepted: 03/04/2016] [Indexed: 12/31/2022] Open
Abstract
Microenvironment and activation signals likely imprint heterogeneity in the lymphatic endothelial cell (LEC) population. Particularly LECs of secondary lymphoid organs are exposed to different cell types and immune stimuli. However, our understanding of the nature of LEC activation signals and their cell source within the secondary lymphoid organ in the steady state remains incomplete. Here we show that integrin alpha 2b (ITGA2b), known to be carried by platelets, megakaryocytes and hematopoietic progenitors, is expressed by a lymph node subset of LECs, residing in medullary, cortical and subcapsular sinuses. In the subcapsular sinus, the floor but not the ceiling layer expresses the integrin, being excluded from ACKR4+ LECs but overlapping with MAdCAM-1 expression. ITGA2b expression increases in response to immunization, raising the possibility that heterogeneous ITGA2b levels reflect variation in exposure to activation signals. We show that alterations of the level of receptor activator of NF-κB ligand (RANKL), by overexpression, neutralization or deletion from stromal marginal reticular cells, affected the proportion of ITGA2b+ LECs. Lymph node LECs but not peripheral LECs express RANK. In addition, we found that lymphotoxin-β receptor signaling likewise regulated the proportion of ITGA2b+ LECs. These findings demonstrate that stromal reticular cells activate LECs via RANKL and support the action of hematopoietic cell-derived lymphotoxin.
Collapse
Affiliation(s)
- Olga G. Cordeiro
- CNRS UPR 3572, University of Strasbourg, Laboratory of Immunopathology and Therapeutic Chemistry/ MEDALIS, Institut de Biologie Moléculaire et Cellulaire, Strasbourg, France
| | - Mélanie Chypre
- CNRS UPR 3572, University of Strasbourg, Laboratory of Immunopathology and Therapeutic Chemistry/ MEDALIS, Institut de Biologie Moléculaire et Cellulaire, Strasbourg, France
- Prestwick Chemical, Blvd Gonthier d'Andernach, Parc d’innovation, 67400, Illkirch, France
| | - Nathalie Brouard
- INSERM, UMR_S949, Etablissement Français du Sang-Alsace, Faculté de Médecine, Fédération de Médecine Translationnelle, Université de Strasbourg, Strasbourg, France
| | - Simon Rauber
- CNRS UPR 3572, University of Strasbourg, Laboratory of Immunopathology and Therapeutic Chemistry/ MEDALIS, Institut de Biologie Moléculaire et Cellulaire, Strasbourg, France
| | - Farouk Alloush
- CNRS UPR 3572, University of Strasbourg, Laboratory of Immunopathology and Therapeutic Chemistry/ MEDALIS, Institut de Biologie Moléculaire et Cellulaire, Strasbourg, France
| | | | - Cécile Bénézech
- BHF Centre for Cardiovascular Science, Queens Medical Research Institute, University of Edinburgh, Edinburgh, United Kingdom
| | - Zhi Li
- Center for Immunology and Infection, Department of Biology, University of York, York, United Kingdom
| | - Anita Eckly
- INSERM, UMR_S949, Etablissement Français du Sang-Alsace, Faculté de Médecine, Fédération de Médecine Translationnelle, Université de Strasbourg, Strasbourg, France
| | - Mark C. Coles
- Center for Immunology and Infection, Department of Biology, University of York, York, United Kingdom
| | - Antal Rot
- Center for Immunology and Infection, Department of Biology, University of York, York, United Kingdom
| | - Hideo Yagita
- Department of Immunology, Juntendo University School of Medicine, Tokyo, 113–8421, Japan
| | - Catherine Léon
- INSERM, UMR_S949, Etablissement Français du Sang-Alsace, Faculté de Médecine, Fédération de Médecine Translationnelle, Université de Strasbourg, Strasbourg, France
| | - Burkhard Ludewig
- Institute of Immunobiology, Kantonspital St. Gallen, 9007, St. Gallen, Switzerland
| | - Tom Cupedo
- Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands
| | - François Lanza
- INSERM, UMR_S949, Etablissement Français du Sang-Alsace, Faculté de Médecine, Fédération de Médecine Translationnelle, Université de Strasbourg, Strasbourg, France
| | - Christopher G. Mueller
- CNRS UPR 3572, University of Strasbourg, Laboratory of Immunopathology and Therapeutic Chemistry/ MEDALIS, Institut de Biologie Moléculaire et Cellulaire, Strasbourg, France
- * E-mail:
| |
Collapse
|